NEW YORK, April 26, 2021 /PRNewswire/ -- Scopus
BioPharma Inc. (Nasdaq: "SCPS") today announced the submission
of an investigational new drug application ("IND") to the United
States Food and Drug Administration ("FDA") for its immuno-oncology
RNA therapy for the treatment of multiple cancers. The IND
filing is a key milestone for the planned Phase 1 clinical trial
for B-cell non-Hodgkin lymphoma to be initiated at City of
Hope.
Scopus is a biopharmaceutical company developing
transformational therapeutics based on groundbreaking scientific
and medical discoveries. City of Hope is a world-renowned
independent research and treatment center for cancer, diabetes and
other life-threatening diseases near Los
Angeles, California.
Joshua R. Lamstein, Chairman of
Scopus BioPharma, stated, "The IND submission to the FDA for a
Phase 1 clinical trial for our lead drug candidate is a key
milestone for Scopus. We are excited about the prospects of
entering the clinic. We believe this, and other imminent
developments, will be significant drivers of shareholder
value."
Scopus' lead drug candidate encompasses both RNA therapy and
immunotherapy by synthetically linking siRNA to an oligonucleotide
TLR9 agonist, creating the potential for targeted gene silencing
with simultaneous TLR stimulation and immune activation in the
tumor microenvironment. This highly-distinctive drug candidate was
developed in the City of Hope laboratories of Hua Yu, Ph.D. and
Marcin Kortylewski, Ph.D. Yu is co-leader of the Cancer
Immunotherapeutics Program and Billy and Audrey L. Wilder Professor
in Tumor Immunotherapy. Kortylewski is an associate professor in
the Department of Immuno-Oncology.
Mr. Lamstein added, "We are privileged to be working with City
of Hope. The IND submission is testament to the respective efforts
and close cooperation of the Scopus and City of Hope teams. We have
developed strong working relationships with Dr. Yu and Dr.
Kortylewski, both preeminent researchers in immuno-oncology, and
other outstanding City of Hope professionals. City of Hope's
collective scientific, manufacturing, clinical, regulatory and
operational capabilities are being coordinated by City of Hope's
Translational Development Center (TDC). The IND submission to the
FDA was accomplished on time and on budget. This was made possible
by the commitment and efforts of the exceptional TDC team brought
together by Ashley Baker Lee, Senior
Vice President, Research Operations. We are extremely grateful to
Ashley and the entire superb research operations team."
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing
transformational therapeutics capitalizing on groundbreaking
scientific and medical discoveries from leading research and
academic institutions. The company's lead drug candidate is a
novel, targeted immuno-oncology RNA therapy for the treatment of
multiple cancers. This drug candidate is highly distinctive,
encompassing both RNA therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor microenvironment.
The company is also developing additional new chemical entities to
treat other serious diseases with significant unmet medical needs,
including systemic sclerosis. Receive updates by following
Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements are subject to risks (including those set forth in the
company's offering circular filed with the U.S. Securities and
Exchange Commission) and uncertainties which could cause actual
results to differ from the forward-looking statements. The company
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections.
Contact
Rodd
Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/scopus-biopharma-announces-ind-submission-to-fda-for-lead-drug-candidate-301276642.html
SOURCE Scopus BioPharma Inc.